AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
33
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Safety

Conditions

Safety, Tolerability, Pharmacokinetics, Healthy Subjects

Trial Timeline

Jul 1, 2015 โ†’ Nov 1, 2015

About AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution

AZD9977, oral suspension + Placebo, oral suspension + AZD9977, oral solution is a phase 1 stage product being developed by AstraZeneca for Safety. The current trial status is completed. This product is registered under clinical trial identifier NCT02484729. Target conditions include Safety, Tolerability, Pharmacokinetics.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02484729Phase 1Completed